Navigation Links
OXiGENE Abstracts Published in ASCO Program

l M. Patterson of the Mount Vernon Cancer Centre indicates that while the study had not yet reached maximum tolerated dose and recruitment is ongoing, the data to date suggest that OXi4503 is tolerated at doses up to 5 mg/m2 without dose-limiting toxicity. Changes in functional activity, as assessed with DCI-MRI and PET imaging evaluations, were observed in three of the eleven patients studied. OXi4503 is a novel, second-generation vascular disrupting agent with potential intrinsic cytotoxicity exerted through an ortho-quinone metabolite. The drug candidate is being evaluated in this Phase I dose escalation and safety study. Based on results to date, OXiGENE currently anticipates initiating further clinical studies with OXi4503 in 2007.

About Combretastatin A4 Phosphate/CA4P (ZYBRESTAT) and OXi4503

ZYBRESTAT is poised to become the first therapeutic product in a novel class of small-molecule drug candidates called vascular disrupting agents (VDAs). The Company currently anticipates starting a Phase II/III pivotal registration study with ZYBRESTAT in June 2007 under a Special Protocol Assessment agreement with the US Food and Drug Administration. Via interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as substantial clinical activity against ATC and other solid tumors in clinical studies to date. Our strategy for optimizing the antitumor activity of ZYBRESTAT is to combine it with other types of therapeutic modalities, including cytotoxic drugs, anti-angiogenesis drugs, and radiation therapy. The rationale for combining ZYBRESTAT with other therapeutic modalities stems from the hypothesis that agents with different and potentially complimentary mechanisms of action and with a non-overlapping toxicity profile may achi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. OXiGENE Announces a Poster Presentation Highlighting Results from its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study MMD-213) at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology
2. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
3. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
4. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
5. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
6. SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
9. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
10. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
11. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: OXiGENE Abstracts Published ASCO Program
(Date:7/2/2015)... June 26, 2015 Research and ... "Vitamin D Market by Analog, Application, End-User & by Region ... their offering. This market is projected to reach ... D in different applications and rising opportunities in countries such ... , Italy , and Brazil ...
(Date:7/2/2015)... 2015 Numotion,s Board of Directors and ... Tamas Feitel has joined the Company as Chief ... highly successful 18 year career at GE serving in ... and productivity to result in significant industry leading growth ... Financial Officer for GE Healthcare Global Services, a $5B ...
(Date:7/2/2015)... 2015 The report "Silage Inoculants ... (Lactobacillus, Pediococcus & Enterococcus), Enzymes (Fibre-digesting & Starch-digesting), Crop-type ... Silage Inoculants & Enzymes Market is expected to reach ... from 2015 to 2020. Browse 75 ... 194 P ages and an in-depth ...
Breaking Medicine Technology:Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 3Numotion Names Tamas Feitel Chief Financial Officer 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4
... LLC , an established CRO providing clinical research services ... biotechnology industry, announced today that President and CEO David ... Clinical Research in Emerging Countries conference July 28-29 ... ) The paradigm of traditional drug development ...
... (NASDAQ: ELGX ), developer and marketer of innovative ... three and six months ended June 30, 2011. ... are pleased with our progress during the quarter and remain ... goals for 2011.  In the second quarter, global revenue grew ...
Cached Medicine Technology:ClinStar to Present on Conducting Clinical Trials in Russia 2Endologix Reports 22% Second Quarter 2011 Revenue Growth 2Endologix Reports 22% Second Quarter 2011 Revenue Growth 3Endologix Reports 22% Second Quarter 2011 Revenue Growth 4Endologix Reports 22% Second Quarter 2011 Revenue Growth 5Endologix Reports 22% Second Quarter 2011 Revenue Growth 6Endologix Reports 22% Second Quarter 2011 Revenue Growth 7Endologix Reports 22% Second Quarter 2011 Revenue Growth 8Endologix Reports 22% Second Quarter 2011 Revenue Growth 9
(Date:7/2/2015)... York, NY (PRWEB) , ... July 02, 2015 ... ... City for Carpal Tunnel treatment and wrist pain treatment. Dr. Lev Kalika, founder ... NYDNRehab – and a leading international authority on the conservative treatment of back, ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... Hand sanitizers ... the current summer flu season, according to fresh water advocate and radio host Sharon ... the hands. Kleyne cautions that for maximum effectiveness, hand sanitizers must be applied correctly ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... the Gelatin Capsule manufacturers. The report is a valuable source of guidance and ... the global and Chinese market for the Gelatin Capsule industry including capacity, production, ...
(Date:7/2/2015)... , ... July 02, 2015 , ... As the world ... differently, but also how they interact with products in their everyday lives. Technology can ... and security systems to home entertainment and safety, as well as making kitchen tasks ...
(Date:7/2/2015)... ... July 02, 2015 , ... As part of the ... Thailand is expressing its gratitude to its patients from all around the world for ... are patients who are off on a dental tour (indeed, Thantakit is one of ...
Breaking Medicine News(10 mins):Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 4Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 2Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 4Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 2Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 3Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 4Health News:Thailand's Longest Established International Dental Center Celebrates Its 70th Anniversary with Promos Galore 2
... March 25 "Today was a monumental day on ... and provide long-term services and supports.We commend the Senate ... and supports in this year,s health care reform. Long-term ... role in America,s health care crisis. The needs are ...
... mice reports a more powerful immune response than from an ... much nicer it would be to get vaccinated by drinking ... , That might someday be the case, thanks to ... probiotics, which are healthy bacteria found in dairy products such ...
... 25 AmeriCares, a nonprofit international relief organization, is ... of lifesaving medicines and medical supplies to its partner, ... The medical aid will help people in the ... diarrhea and chronic diseases, in addition to pre-natal vitamins ...
... for best health plans in the countryEAGAN, Minn., ... of Minnesota announced today that it has earned ... health plans by the National Committee on Quality ... a private 501(c)(3) non-profit organization dedicated to driving ...
... March 25 Persons who purchased or paid for (in ... other entities that reimbursed for (in whole or in part) ... be eligible for relief as part of a $28 million ... GlaxoSmithKline ("GSK") manufactured between April 1, 2002 and March 4, ...
... Friday 20 March, US researcher Dr. Chris Beecher from the ... an N-methyl derivative of the amino acid glycine, at the ... a colleague of lead author Dr. Arun Sreekumar. The research ... 1,000 small molecules in tissues associated with prostate cancer. These ...
Cached Medicine News:Health News:Statement From Larry Minnix, President & CEO of the American Association of Homes and Services for the Aging, on the Senate Finance Committee Hearing 'The Role of Long-term Care in Health Reform' and the Reintroduction of the CLASS Act 2Health News:Statement From Larry Minnix, President & CEO of the American Association of Homes and Services for the Aging, on the Senate Finance Committee Hearing 'The Role of Long-term Care in Health Reform' and the Reintroduction of the CLASS Act 3Health News:Oral Yogurt 'Vaccine' Could Blunt Ouch Factor 2Health News:AmeriCares and International Medical Corps Partner to Bring Lifesaving Aid to Chad 2Health News:Blue Cross Earns Highest National NCQA Accreditation Status for Quality Service and Care 2Health News:Proposed Settlement Will Make Up to $28 Million Available to Individuals Who Purchased and Companies That Reimbursed for Paxil CR(R) 2Health News:A new approach to prostate cancer detection 2
Curved 20 mm serrated jaws. Ring handle with ratchet lock and dull finish. Most popular size or model. Overall length 3.9 inches...
Curved 21 mm serrated jaws. Ring handle with ratchet lock. Non-magnetic and dull finish. Overall length 4.7 inches....
Shafts angled 45 degrees with 10 mm jaws. Serrated handle with polished finish. Smooth jaws. Most popular size or model....
Straight shafts with 13 mm crisscross serrated platform with polished finish. Wide serrated handle....
Medicine Products: